{"nctId":"NCT00092547","briefTitle":"A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)","startDateStruct":{"date":"2003-10-08","type":"ACTUAL"},"conditions":["Human","Papillomavirus Infections"],"count":1781,"armGroups":[{"label":"qHPV Vaccine in Base Study","type":"EXPERIMENTAL","interventionNames":["Biological: V501"]},{"label":"Placebo in Base Study","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Comparator: Placebo"]},{"label":"qHPV Vaccine in Extension Study","type":"EXPERIMENTAL","interventionNames":["Biological: V501"]}],"interventions":[{"name":"V501","otherNames":["GARDASIL™"]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy adolescents and preadolescents with no prior sexual history\n\nExclusion Criteria:\n\n* Subjects with compromised immune system or have a history of severe allergic reaction","healthyVolunteers":true,"sex":"ALL","minimumAge":"9 Years","maximumAge":"15 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Reporting Serious Adverse Experiences (SAEs) Through Month 18","description":"Tolerability as assessed by the number of participants with clinical adverse experiences through Month 18. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \"other important medical event\" based on medical judgment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting SAEs From Month 18 Through Month 37","description":"Tolerability as assessed by the number of participants with clinical adverse experiences from Month 18 through Month 37","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Other (Non-serious) AEs Through Month 18","description":"Tolerability as assessed by the number of participants with clinical adverse experiences through Month 18","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"918","spread":null},{"groupId":"OG001","value":"340","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 72","description":"A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","spread":null},{"groupId":"OG001","value":"91.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"96.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null},{"groupId":"OG001","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":null},{"groupId":"OG001","value":"79.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) for Anti-HPV 6, 11, 16, and 18 at Month 72","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118.9","spread":null},{"groupId":"OG001","value":"113.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135.7","spread":null},{"groupId":"OG001","value":"137.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"521.2","spread":null},{"groupId":"OG001","value":"485.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.9","spread":null},{"groupId":"OG001","value":"67.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers for Anti-HPV 6, 11, 16, and 18 at Month 96","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null},{"groupId":"OG001","value":"91.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.5","spread":null},{"groupId":"OG001","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"325.5","spread":null},{"groupId":"OG001","value":"387.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.6","spread":null},{"groupId":"OG001","value":"48.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 96","description":"A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"91.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":null},{"groupId":"OG001","value":"93.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.9","spread":null},{"groupId":"OG001","value":"69.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers for Anti-HPV 6, 11, 16, and 18 at Month 126","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null},{"groupId":"OG001","value":"99.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.6","spread":null},{"groupId":"OG001","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"320.1","spread":null},{"groupId":"OG001","value":"351.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","spread":null},{"groupId":"OG001","value":"39.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 126","description":"A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.0","spread":null},{"groupId":"OG001","value":"91.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null},{"groupId":"OG001","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"96.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","spread":null},{"groupId":"OG001","value":"65.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting SAEs Related to Study Vaccine or to a Study Procedure in the Long-term Follow-up","description":"A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \"other important medical event\" based on medical judgment. SAEs considered by the investigator to be possibly, probably, or definitely related to study vaccine or a study procedure were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 1 Postdose 3 (Month 7)","description":"A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 12 Postdose 3 (Month 18).","description":"A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 18 Postdose 3 (Month 24)","description":"A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 24 Postdose 3 (Month 30)","description":"A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Original qHPV Vaccine Participants Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 31 Postdose 3 (Month 37).","description":"A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in the Extension Group Who Are Seropositive for HPV Types 6, 11, 16, and 18 at Month 1 Postdose 3 of qHPV (Month 37)","description":"A participant is considered seropositive for a given HPV type if he or she has a cLIA titer at or above the serostatus cutoff for that HPV type. Serostatus cutoffs are ≥ 20 mMU/mL for HPV 6 and 16, ≥ 16 mMU/mL for HPV 11, and ≥ 24 mMU/mL for HPV 18.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 1 Postdose 3 of qHPV Vaccine (Month 7)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"929.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1362.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5512.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1278.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 12 Postdose 3 of qHPV Vaccine (Month 18)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"219.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"296.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1314.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"203.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 18 Postdose 3 of qHPV Vaccine (Month 24)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"206.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"932.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 24 Postdose 3 of qHPV Vaccine (Month 30)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"146.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"826.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers of Original qHPV Vaccine Cohort for Anti-HPV 6, 11, 16, and 18 at Month 31 Postdose 3 of qHPV Vaccine (Month 37)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"680.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers in the Extension Group for Anti-HPV 6, 11, 16, and 18 at Month 1 Postdose 3 of qHPV Vaccine (Month 37)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"768.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1041.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4312.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"830.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Combined Incidence of HPV 6/11/16/18-related Persistent Infection and HPV 6/11/16/18-related CIN, AIS, VIN, VaIN, Genital Warts, and Cervical/Vaginal/Vulvar Cancer in Females","description":"The HPV types were determined by polymerase chain reaction (PCR) testing. The combined incidence of HPV 6/11/16/18-related persistent infection and HPV 6/11/16/18-related cervical intraepithelial neoplasia (CIN), adenocarcinoma in situ (AIS), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), genital warts, and cervical/Vaginal/vulvar cancer was assessed in female participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Combined Incidence of HPV 6/11/16/18-related Persistent Infection and HPV 6/11/16/18-related PIN, Genital Warts, and Penile/Perineal/Perianal Cancer in Males","description":"The HPV types were determined by PCR testing. Combined incidence of HPV 6/11/16/18-related persistent infection and HPV 6/11/16/18-related penile/perineal/perianal intraepithelial neoplasia (PIN), genital warts, and penile/perineal/perianal cancer was assessed in male participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":1165},"commonTop":["Injection site pain","Headache","Injection site erythema","Injection site swelling","Pyrexia"]}}}